



THE UNIVERSITY OF CHICAGO

ANNUAL UPDATES FROM **ASH 2024**

PRACTICE CHANGING ABSTRACTS

FRIDAY, FEBRUARY 28, 2025

HYBRID FORMAT: VIRTUAL & IN-PERSON ATTENDANCE

COURSE DIRECTOR

Michael Bishop, MD | Professor of Medicine
Director of the Jonas Center for Cellular Therapy
University of Chicago Medicine

www.ChicagoPostASH.com

CONTINUING EDUCATION ACCREDITATION BY UNIVERSITY OF CHICAGO
THIS ACTIVITY IS APPROVED FOR AMA PRA CATEGORY 1 CREDIT™.



AT THE FOREFRONT

**UChicago
Medicine**



THE UNIVERSITY OF CHICAGO

ANNUAL UPDATES FROM **ASH 2024**

REGISTER TODAY!

www.ChicagoPostASH.com

QUESTIONS? Contact Meeting Achievements at
kristen@meetingachievements.com -or- 219.465.1115



COURSE DESCRIPTION

This activity aims to connect community-based providers and academic oncologists to improve care and outcomes for patients with hematologic malignancies. By focusing on early treatment options and innovative medical advances, including CAR T-cell therapy, novel immunotherapies, and targeted agents, the program strives to reduce cancer-related mortality.

Participants will gain insights into the latest scientific advancements and approaches for managing both newly diagnosed and relapsed blood cancers. It also will emphasize strategies to enhance patient management and care, fostering discussions on rapid treatment developments and critical considerations for treatment sequencing.

Through this collaboration, healthcare professionals will learn best practices for treating hematologic cancers and understand when to refer patients for specialized care at advanced treatment centers such as the University of Chicago Medical Center. Ultimately, the goal is to refine practice paradigms across all treatment settings, ensuring patients receive the most effective and timely care possible including access to clinical trials options.

KEYNOTE SPEAKER



Katy Rezvani, MD, PhD

VP and Head of the MDACC Cell Therapy
Institute for Innovation and Discovery
Professor of Medicine
Sally Cooper Murray Endowed Chair
in Cancer Research
Medical Director of the MD Anderson GMP
and Cell Therapy Laboratory
University of Texas MD Anderson Cancer Center

Dr. Rezvani will be presenting on
**Engineered NK Cells: A New Era in
Targeted Cancer Therapy**

TARGET AUDIENCE

This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.

FEATURING: Dedicated Pharmacy and Allied Health & APP Focused Sessions

CONFERENCE LOCATION

IN-PERSON: Convene | 333 North Green Street | Chicago, Illinois 60607

VIRTUAL: Log in information will be sent 72 hours prior to conference.

MORE INFORMATION CAN BE FOUND ON OUR WEBSITE OR BY SCANNING THE QR CODE ABOVE.



AT THE FOREFRONT
**UChicago
Medicine**